AN ANTIBODY treatment hailed as a "major breakthrough" against Covid by President Donald Trump failed to reduce deaths or severe illness in clinical trials.
Convalescent plasma, donated by patients who have recovered from the virus and packed with their antibodies, has been effective in other infectious diseases such as measles and influenza.
Countries, including Britain, have been stockpiling blood plasma so the treatment could be rolled out if it proved effective, and in August President Trump issued an emergency authorisation to allow its use in the US.
Mr Trump went on to receive Regeneron, an experimental treatment created with laboratory-grown antibodies rather than donor plasma, when he contracted Covid earlier this month.
READ MORE: Health board in Covid hotspot says admissions now exceeding peak in first wave
However, a new randomised control study, published today in the British Medical Journal (BMJ), found that plasma transfusions made no difference to outcomes in Covid patients.
The study was carried out in India and involved 450 adults hospitalised with moderate illness.
Half received only standard treatment and half standard treatment plus convalescent plasma.
READ MORE: Freeman warns it is 'not acceptable' to vaccinate oldest last in flu drive
In both groups around 20 per cent of patients progressed to severe illness or died from any cause, the researchers found.
Professor Aparna Mukherjee, of the Indian Council of Medical Research, who co-led the research, said: “As a potential treatment for patients with moderate covid-19, convalescent plasma showed limited effectiveness.
“Future research could explore using only plasma with high levels of neutralising antibodies, to see if this might be more effective.”
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules hereLast Updated:
Report this comment Cancel